Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit the release ...
Nucana (NCNA) has released an update. NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with ...
Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit ...
EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in ...
Following treatment with NUC-3373 plus docetaxel, the patient achieved Stable Disease for 7 months. Professor David Harrison, NuCana's Head of Translational Medicine, stated: "We previously presented ...
EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in ...
Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, Nov. 11 ...
MT Newswires on MSN2d
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday TradingEuropean equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index. From continental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback